Journal
ONCOLOGIST
Volume 8, Issue 2, Pages 149-160Publisher
ALPHAMED PRESS
DOI: 10.1634/theoncologist.8-2-149
Keywords
pancreatic ductal carcinoma; antineoplastic agents; tissue inhibitor of metalloproteinases; epidermal growth factor receptor; ras gene; angiogenesis inhibitors
Categories
Ask authors/readers for more resources
Pancreatic carcinoma is a commonly occurring cancer that tends to present late in its course when potentially curative surgical treatment is not possible. The majority of patients are, therefore, candidates for systemic therapy. We review the patient and disease-related factors that contribute to the difficulties in the medical management of this condition and discuss new methods of assessing response to treatment, including the introduction of more clinically relevant novel end points such as clinical benefit response. We review the current trial literature examining the use of conventional cytotoxic agents in this disease, both as single agents and in combination. We also review the use of more novel targeted agents and examine their potential utility in this disease. The use of the farnesyl transferase inhibitors, matrix metalloproteinase inhibitors, epidermal growth factor receptor antagonists, and angiogenesis inhibitors is discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available